|
|
|
|
|
|
|
|
|
Webinar: Every Day Counts: Raising the Bar in Gene Therapy with Science & Structure
|
Join Viralgen and QbDVision as they reveal how a groundbreaking partnership accelerated a first-in-class gene therapy from concept to commercial readiness in just 3 months instead of 12. Using QbDVision’s Digital CMC platform, Viralgen standardized documentation, improved transparency, and streamlined tech transfers—establishing a scalable, data-driven model for faster, more efficient gene therapy manufacturing. Click here to learn more.
|
|
|
|
|
|
Video | Aliri Bioanalysis
|
Learn about a novel LCMS assay for 4Β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.
|
|
|
|
|
|
Video | Cell & Gene
|
This segment from the Cell & Gene Live digital event explores intermediate storage options for cell therapy products and the factors to consider when working with these vendors.
|
|
|
|
|
|
Webinar | PBS Biotech, Inc.
|
Discover advanced bioreactor systems and expert development services that can help you streamline your process and accelerate your path to clinical or commercial success.
|
|
|
|
|
|
Video | Ori Biotech
|
Henrik Anderson, Head of Cell Therapy Technology Development at Bristol Myers Squibb, explores how early planning, automation, and economic discipline can help scale the impact of cell therapies.
|
|
|
|
|
|
Video | Andelyn Biosciences
|
A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.
|
|
|
|
|
|
Video | Cytiva
|
Streamline CAR T cell therapy manufacturing with an end-to-end solution featuring two automated systems that optimize every stage from cell isolation to final therapeutic dose.
|
|
|
|
|
|
Video | Life Science Leader
|
On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer.
|
|
|
